Researchers at the UK's University of Manchester and the University of York have discovered a new enzyme called RedAm that can aid the cheaper and quicker production of a drug for Parkinson’s disease.

Found in a fungus called Aspergillus oryzae, RedAm is a biocatalyst with the capacity to enhance reductive amination process, which is considered as an important process in the synthesis of pharmaceutical products’ chemical building blocks known as chiral amines.

Developed by a team lead by the Manchester Institute of Biotechnology (MIB) chemical biology professor Nick Turner, the enzyme is expected to majorly impact monoamine oxidase (MAO) inhibitors such as Rasagiline.

Rasagiline is known to increase a substance acting on motor function processes in the brain of patients suffering from Parkinson’s disease.

"It is the first enzyme of its kind that has these properties and has the potential to improve the production of this and other important drugs."

The use of RedAms in the chiral amine synthesis is claimed to result in the decrease of time required for synthesis, cost and the manpower needed for the production of the chiral amines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Professor Nick Turner said: “This is a very exciting discovery from both a chemistry and pharmaceutical perspective.

“It is the first enzyme of its kind that has these properties and has the potential to improve the production of this and other important drugs.”

In addition to the medication for Parkinson’s, the enzyme is expected to aid in the manufacture of other drugs based on a previous analysis, which showed around 40% of new chemical entities (NCEs) comprise one or more building blocks of chiral amine.


Image: New enzyme for cheaper and quicker production of drugs. Photo: courtesy of the University of Manchester.